The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study.
Allyson J. Ocean
Research Funding - Immunomedics
Michael J. Guarino
Research Funding - Immunomedics
Kenneth Lee Pennington
Research Funding - Immunomedics
Gregory M. Springett
Research Funding - Immunomedics
Seza A Gulec
Research Funding - Immunomedics
Tanios S. Bekaii-Saab
Research Funding - Immunomedics
Alberto J. Montero
Research Funding - Immunomedics
Edith P. Mitchell
Research Funding - Immunomedics
John S Kauh
Research Funding - Immunomedics
Max W. Sung
Research Funding - Immunomedics
David V. Gold
No relevant relationships to disclose
Heather Horne
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
William A. Wegener
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
David M. Goldenberg
Employment or Leadership Position - Immunomedics (B)
Stock Ownership - Immunomedics (B)